Diabetes, Vol 40, Issue 11 1480-1487, Copyright © 1991 by American Diabetes Association

ARTICLES

Evolution of insulin resistance in New Zealand obese mice

MC Veroni, J Proietto and RG Larkins
University of Melbourne, Department of Medicine, Royal Melbourne Hospital, Parkville, Australia.

The etiology of non-insulin-dependent diabetes mellitus (NIDDM) is not known. Hyperglycemia is due to increased hepatic glucose production (HGP), decreased glucose uptake, and impaired insulin secretion. It is unknown if these defects are coinherited or if one precedes and causes the others. The aim of this study was to determine the earliest defects in the evolution of the syndrome in the New Zealand obese (NZO) mouse, a polygenic model of NIDDM. NZO and control NZC mice were studied at 4-5 and 20 wk of age. Glucose turnover and glucose uptake in individual tissues were measured basally and during a hyperinsulinemic clamp. First-phase insulin secretion was measured after an intravenous glucose load. HGP was higher in the NZO mice both basally and during the clamp at both ages. At 4-5 wk of age, there was evidence of insulin insensitivity in brown adipose tissue, soleus, diaphragm, red quadriceps, and red gastrocnemius but not in heart, white quadriceps, and white gastrocnemius. In 20-wk-old mice, insulin responsiveness was decreased in white and brown adipose tissue and soleus muscle but not in heart, diaphragm, red and white quadriceps, and red and white gastrocnemius. First-phase insulin secretion (percentage rise above basal) 3 min after the glucose bolus was impaired in NZO mice at both ages. We conclude that hepatic glucose overproduction, brown adipose tissue and skeletal muscle insulin resistance, and impaired first-phase insulin secretion are all early abnormalities in the NZO mouse.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. M. Clee and A. D. Attie The Genetic Landscape of Type 2 Diabetes in Mice Endocr. Rev., February 1, 2007; 28(1): 48 - 83. [Abstract] [Full Text] [PDF]

				J. H. Kim, T. P Stewart, M. Soltani-Bejnood, L. Wang, J. M Fortuna, O. A Mostafa, N. Moustaid-Moussa, A. M Shoieb, M. F McEntee, Y. Wang, et al. Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice. J. Endocrinol., November 1, 2006; 191(2): 437 - 446. [Abstract] [Full Text] [PDF]

				M. K. Mohammad, M. Morran, B. Slotterbeck, D. W. Leaman, Y. Sun, H. v. Grafenstein, S.-C. Hong, and M. F. McInerney Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse Int. Immunol., July 1, 2006; 18(7): 1101 - 1113. [Abstract] [Full Text] [PDF]

				B. J. Lamont, S. Visinoni, B. C. Fam, M. Kebede, B. Weinrich, S. Papapostolou, H. Massinet, J. Proietto, J. Favaloro, and S. Andrikopoulos Expression of Human Fructose-1,6-Bisphosphatase in the Liver of Transgenic Mice Results in Increased Glycerol Gluconeogenesis Endocrinology, June 1, 2006; 147(6): 2764 - 2772. [Abstract] [Full Text] [PDF]

				H. S. Jurgens, A. Schurmann, R. Kluge, S. Ortmann, S. Klaus, H.-G. Joost, and M. H. Tschop Hyperphagia, lower body temperature, and reduced running wheel activity precede development of morbid obesity in New Zealand obese mice. Physiol Genomics, April 13, 2006; 25(2): 234 - 241. [Abstract] [Full Text] [PDF]

				C. Knouff and J. Auwerx Peroxisome Proliferator-Activated Receptor-{gamma} Calls for Activation in Moderation: Lessons from Genetics and Pharmacology Endocr. Rev., December 1, 2004; 25(6): 899 - 918. [Abstract] [Full Text] [PDF]

				E. H. Leiter and P. C. Reifsnyder Differential Levels of Diabetogenic Stress in Two New Mouse Models of Obesity and Type 2 Diabetes Diabetes, February 1, 2004; 53(90001): S4 - 11. [Abstract] [Full Text]

				M. Igel, W. Becker, L. Herberg, and H.-G. Joost Hyperleptinemia, Leptin Resistance, and Polymorphic Leptin Receptor in the New Zealand Obese Mouse Endocrinology, October 1, 1997; 138(10): 4234 - 4239. [Abstract] [Full Text] [PDF]